Form 4: C4 Therapeutics Director Donna Grogan Receives Stock in Lieu of Cash Compensation

Director Donna Grogan acquired 2,836 shares of C4 Therapeutics common stock in lieu of cash compensation, while disposing of 26,468 shares on July 1, 2024.

Summary

• On July 1, 2024, Donna Grogan, a director of C4 Therapeutics, acquired 2,836 shares of common stock.
• These shares were issued as compensation for her services as a non-employee director, in lieu of cash, according to the Issuer's Non-Employee Director Compensation Policy.
• The price of the stock was $4.85 per share, based on the closing market price on July 1, 2024.
• Grogan also disposed of 26,468 shares on the same day.
• Following these transactions, Grogan's beneficial ownership of C4 Therapeutics common stock is updated.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director acquiring shares is generally positive, the simultaneous disposal of a larger number of shares tempers the positive signal.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Negatives

• The disposal of 26,468 shares by the director on the same day could be interpreted negatively by investors.

Risks

• The Form 4 filing itself doesn't inherently present risks, but the market's reaction to the director's stock activity could impact the company's stock price.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The market often scrutinizes these filings for signals about management's view of the company's prospects.

Stakeholder Impact

• Shareholders may react to the director's stock transactions, potentially influencing the stock price.
• The company's reputation could be affected depending on how the market interprets the insider trading activity.

Key Dates